Background-Little is known about the impact of bleeding site on mortality after percutaneous coronary intervention.
B leeding is one of the most common noncardiac procedurerelated adverse events of percutaneous coronary intervention (PCI). 1 Ample evidence exists that periprocedural bleeding is associated with a poor clinical outcome, including an increased risk of mortality, across a wide spectrum of patients treated with PCI. [2] [3] [4] [5] [6] Apart from being a sign of poor health, bleeding itself may set into motion a cascade of adverse events that may increase morbidity and mortality after PCI. 7 Accordingly, current American College of Cardiology, American Heart Association PCI guidelines 8 state that all patients should be evaluated for the risk of bleeding complications before PCI (class I, level of evidence C), and various avoidance bleeding strategies have been adopted. 9 Bleeding occurring in the setting of PCI emerges either at the site of vascular access (including spreading to adjacent tissues) or at other locations not related to vascular access site (non-access site bleeding). Few data exist on the impact of bleeding site on the outcome after PCI. 10, 11 These studies, however, did not characterize patients according to bleeding site or assess factors that may predispose for access or non-access site bleeding. Although there are signals for a differentiated effect of various antithrombotic therapies on access and non-access site bleeding, 10, 12, 13 little is known about the relationship between site of bleeding and clinical outcome. Comparison of the impact of access and non-access site bleeding is further hampered by the use of various bleeding definition criteria, with substantial differences in their sensitivity to identify clinically relevant bleeding events. Although, the use of bleeding avoidance strategies have been partially successful, bleeding still remains a frequent complication of PCI and is associated with mortality. 14 Recently, a unified bleeding definition system has been proposed by the Bleeding Academic Research Consortium (BARC), 15 validated and found to be more sensitive than other commonly used bleeding definition criteria. 16 In the present study, we used BARC criteria to evaluate bleeding events after PCI, with 3 objectives: first, to assess the association between access site and non-access site bleeding within the first 30 days after PCI with mortality; second, to investigate factors associated with access site and non-access site bleeding; and third, to investigate whether bleeding events of different locations improve the discriminatory power of the multivariable models on mortality prediction.
Methods Patients
This study represents a pooled patient-level analysis of 14 180 patients recruited in 7 randomized clinical trials: the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment (ISAR-REACT), 17 the Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET), 18 the Intracoronary Stenting to Abrogate Restenosis in Small Arteries (ISAR-SMART)-2, 19 the ISAR-REACT-2, 20 ISAR-REACT-3, 21 ISAR-REACT-3A, 22 and ISAR-REACT-4. 23 Patients in the 7 trials were recruited between June 2000 and May 2011. The first 4 trials were randomized, placebo-controlled trials addressing whether benefit existed from the glycoprotein IIb/IIIa inhibitor abciximab in patients with various presentations of coronary artery disease. The ISAR-REACT-3 trial was a randomized, double-blind trial comparing bivalirudin with unfractionated heparin in patients with stable or unstable angina. The ISAR-REACT-3A trial was a prospective, multicenter single-arm, open-label trial in which patients receiving 100 U unfractionated heparin were compared with those who received 140 U unfractionated heparin in the ISAR-REACT-3 trial. The ISAR-REACT-4 trial was a randomized, double-blind trial that compared bivalirudin with abciximab plus unfractionated heparin (70 U/kg) in patients with non-ST-segment-elevation myocardial infarction. Patients in all trials underwent PCI after receiving 325 to 500 mg of aspirin and 600 mg loading dose of clopidogrel. Detailed inclusion/exclusion criteria are provided in the online-only Data Supplement.
In all 7 trials, written informed consent was required for patient participation. The trials were initially approved by the Ethics Committee of the Technische Universität München, Munich, Germany followed by the local ethics committees of the participating centers.
Antithrombotic Drugs
Detailed study protocols on the use of antithrombotic/anticoagulant drugs were provided in the primary publications of each trial. In the ISAR-REACT, ISAR-SWEET, ISAR-SMART, ISAR-REACT-2, and ISAR-REACT-4, patients in the abciximab arm received a bolus of abciximab 0.25 mg/kg weight followed by an infusion of 0.125 µg/ kg per minute (a maximum of 10 µg/min) for 12 hours and a 70 U/kg bolus of unfractionated heparin intravenously. In the ISAR-REACT-3 and ISAR-REACT-4 trials, patients assigned to bivalirudin, received a bolus of 0.75 mg of bivalirudin per kilogram, followed by an infusion of 1.75 mg/kg per hour for the duration of the procedure. In all these trials, patients assigned to placebo or unfractionated heparin received a bolus of 140 U of heparin per kilogram of weight. The 100 U arm of the ISAR-REACT-3A trial received 1 open-label bolus of 100 U/kg bodyweight unfractionated heparin, which was compared with the 140 U unfractionated heparin arm of the ISAR-REACT-3 (historical control).
Coronary stenting with either bare-metal or drug-eluting stents was performed according to standard practice. Femoral artery route was used for vascular access in all but 6 patients. Sheaths were removed and manual compression was applied as soon as the activated partialthromboplastin time fell <50 seconds. Vascular access closure devices were used in fewer than 10% of the patients. Postprocedural therapy included aspirin (80-325 mg/d indefinitely), clopidogrel (75-150 mg/d until discharge but for no longer than 3 days, followed by 75 mg/d for ≥1 month, in patients with bare-metal stents, or ≥6 months, in patients with drug-eluting stents). Other cardiac medications were prescribed at the discretion of the patient's physician.
End Points and Definitions
The primary outcome of this study was 1-year mortality. Bleeding events within the 30 days after PCI were defined using the BARC criteria 15 (online-only Data Supplement). BARC bleeding criteria were retrospectively applied. Every case of bleeding was reported in each of the trials and was included in this pooled analysis. For every case with bleeding, source documentation was available and was re-evaluated. Information on localization, imaging tests, hemoglobin level, hematocrit, and blood transfusion was reanalyzed. For patients who underwent coronary artery bypass surgery during the index hospitalization (n=25 patients), patients' charts were re-examined for the occurrence of bleeding and its characteristics. Because the primary outcome of this analysis was mortality, bleeding events potentially belonging to the BARC class 5 (fatal bleeding) were distributed to other classes according to their initial characterization. Bleeding site and other characteristics were determined by local investigators and recorded on the case report form. For this analysis, bleeding was defined as access and non-access site. Access site bleeding was defined as any bleeding arising from the arterial access site area, including bleeding that spread to adjacent tissues (such as the retroperitoneal space). The presence and size of retroperitoneal bleeding was confirmed/assessed by computed tomography when clinically indicated, and data were forwarded to the coordinating center. Non-access site bleeding was defined as bleeding not arising from the arterial access site. In the case of occurrence of >1 bleeding event, only 1 bleeding event per patient was considered for analysis. In the latter scenario, the location of bleeding was defined as the site with the largest bleed. Bleeding of undefined location after negative imaging tests was considered as non-access site bleeding. Adjudication and classification
WhAT IS KNOWN
• Bleeding complications during percutaneous coronary intervention are associated with a poor clinical outcome.
• The limited evidence available suggests that there are differences in the prognostic impact of bleeding events depending on the location of bleeding with a stronger association between bleeding and prognosis in non-access site bleeding.
WhAT ThE STuDy ADDS
• This study showed that access and non-access site bleeding events during percutaneous coronary intervention are independently associated with an increased risk of 1-year mortality.
• The association between bleeding occurrence and mortality was significantly stronger for non-access than for access site bleeding.
• Although both access and non-access site bleeding
were independently associated with the increased risk of mortality, only non-access site bleeding increased the discriminatory power of the multivariable model on mortality prediction. of the bleeding events were performed by personnel not involved in the primary studies.
All patients were either seen by their physician or interviewed by telephone at 30 days, 6 months, and 1 year after the procedure; patients with cardiac complaints underwent a complete clinical, ECG, and laboratory evaluation at those time points. Information on deaths was obtained from hospital records, death certificates, or telephone contact with relatives of the patient or referring physician. The local research coordinators collected the data and forwarded them to the data coordinating center. Angiographic data were analyzed by the same quantitative angiographic core laboratory.
Statistical Analysis
The data are presented as median (25th, 75th percentiles), Kaplan-Meier estimates or counts (%). The 1-sample Kolmogorov-Smirnov test was used to assess the normality of data distribution. Continuous data were compared with the Kruskal-Wallis rank-sum test and the Tukey honestly significant difference test. Categorical data were compared with χ 2 test. A multinomial log-linear model was used to assess correlates of access and non-access site bleeding. All variables of Table 1 were entered into the model. The survival analysis was performed using the Kaplan-Meier method and differences in survival were compared with the log-rank test. Multivariable Cox proportional hazards model was used to assess independent correlates of 1-year mortality. All variables in Table 1 , plus access and non-access site bleeding, were entered into the model. The proportional hazards assumption was checked by the method of Grambsch and Therneau. 24 In all multivariable models, we specifically adjusted for the type of therapy received by the patients. In addition, to account for the type of the study, a random effect for study was included in the models. Discriminatory power of multivariable model(s) before (with baseline variables only) and after inclusion of access or non-access site bleeding events was assessed by calculating the integrated discrimination improvement according to Pencina et al. 25 All analyses were performed using R package. A 2-sided P value < 0.05 was considered to indicate statistical significance.
Results

Characteristics
Bleeding events within the first 30 days after PCI occurred in 1510 patients (10.6%). Bleeding at the arterial access site occurred in 905 patients (6.4% of patients; 60% of bleeding events). Non-access site bleeding occurred in 605 patients (4.2% of patients; 40% of bleeding events). Of 605 patients in the group with non-access site bleeding, 120 patients also had access site bleeding. Baseline characteristics of patients are shown in Table 1 . With the exception of proportions of patients with diabetes mellitus (excluding those on insulin therapy), current smoking, prior coronary artery bypass surgery, and narrowed coronary arteries (including multivessel disease), all other characteristics seem to differ significantly between patients who had and had not bled. Baseline characteristics of patients with access site versus those with non-access site bleeding were compared. Patients with non-access site bleeding were older (P=0.037), more likely to have diabetes mellitus requiring insulin therapy (P<0.001), presented more often with an acute coronary syndrome (P=0.002) and elevated troponin level (P=0.014), had higher serum creatinine levels (P=0.017), and were less likely to have hypercholesterolemia (P=0.033) and had lower left ventricular ejection fraction (P=0.003) than patients with access site bleeding. The remaining characteristics did not differ among patients with access and non-access site bleeding. Within the group with non-access site bleeding, we compared patients who also had access site bleeding with those with isolated non-access site bleeding (n=485). Except for the proportion of patients with elevated troponin level, which was higher among patients with isolated non-access site bleeding (33.6% versus 22.5%; P=0.018), none of the remaining baseline characteristics differed significantly between these 2 subgroups.
Bleeding severity in patients with access and non-access site bleeding is shown in Table 2 . Of note, patients with non-access bleeding had more severe bleeding (reflected by a BARC class ≥2) than patients with access site bleeding (74.4% versus 47.3%; P<0.001; Table 2 ).
Predictors of Access and Non-Access Site Bleeding
Multiple logistic regression was used to assess independent predictors of access and non-access site bleeding (see Methods section of this article for variables entered into the model). This revealed that age, sex, body mass index, arterial hypertension, and platelet count were independently associated with an increased risk of access site bleeding. Variables that were independently associated with nonaccess bleeding were age, sex, body mass index, arterial hypertension, hypercholesterolemia, presentation with an acute coronary syndrome, left ventricular ejection fraction, and platelet count. The adjusted odds ratios and the direction of association with bleeding are shown in Table 3 . The assessment of the role of antithrombotic therapy on access and non-access site bleeding was intentionally confined to randomized comparisons as used in the primary randomized studies (Table 4 ). 
One-year Clinical Outcome
One-year follow-up was complete in all but 352 patients (2.5%). In patients with incomplete follow-up, the median follow-up (25th, 75th percentiles) was 6.7 (2. Figure. There was no significant difference in the 1-year mortality among patients with isolated non-access site (n=51 deaths) compared with those with combined non-access and access site (n=9 deaths) bleeding (Kaplan-Meier estimates of mortality 10.6% and 7.5%, respectively; P=0.298).
Deaths according to bleeding severity and location are shown in Tables 5 and 6. Cardiac and noncardiac deaths occurred in 248 patients (60%) and 166 patients (40%), respectively. Noncardiac causes were as follows: cancer (n=57), acute infection and sepsis (n=22), stroke (n=19), complications of surgery (n=12), chronic renal failure (n=7), accidents/suicide (n=5), multiorgan failure (n=4), pulmonary embolism (n=3), pulmonary edema (n=2), and unknown (n=35).
The multivariable Cox proportional hazards model was used to identify independent correlates of 1-year mortality (see Methods section of this article for variables entered into the model). The results of Cox model are shown in Table 7 . There was no heterogeneity across the studies (random effect for trial was associated with a P=0.28). Access and nonaccess site bleeding were each independently associated with an increased risk of mortality showing a 1.72-and 2.78-fold increase in the adjusted risk for mortality, respectively, compared with patients who did not bleed. The adjusted risk of mortality associated with non-access site was 62% higher than the adjusted risk for mortality associated with access site bleeding ( Table 7) .
The impact of bleeding on the discriminatory power of multivariable model(s) on mortality was assessed by calculating the integrated discrimination improvement. The inclusion of access site bleeding was not associated with an increase of the discriminatory power of the model on mortality compared with the model without bleeding (absolute and relative integrated discrimination improvement, 0.0015 and 2.7%, respectively; P=0.084). In contrast, the inclusion of non-access site bleeding was associated with a significant increase of the discriminatory power of the model on prediction of mortality compared with the model without bleeding (absolute and relative integrated discrimination improvement, 0.005 and 8.9%, respectively; P=0.031).
Discussion
The 4 most important findings of the present study are as follows: (1) access and non-access site bleeding events occurring in the setting of PCI are independently associated with an increased risk of 1-year mortality. (2) The association between bleeding occurrence and mortality is significantly stronger for non-access site bleeding than for access site bleeding. (3) Although access and non-access site bleeding share similar predisposing factors, patients with non-access site bleeding have a more adverse cardiovascular risk profile. (4) Non-access site bleeding increased the discriminatory power of the multivariable model for mortality prediction, whereas access site bleeding did not. Thus, the site of bleeding offers prognostic information that is independent of and supplementary to that provided by cardiovascular risk factors and relevant clinical variables. The impact of the location of bleeding on outcome has been addressed in few studies whose results have been inconsistent. 10, 11 In a recent study by Verheugt et al 10 that included a combined data set from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events-2, Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY), and Harmonizing
Outcomes with Revascularization and Stents in Acute Myocardial Infarction trials, bleeding events assessed by thrombolysis in myocardial infarction criteria occurred in 5.3% of the patients; nearly two thirds had a non-access site location. In that study, both access and non-access site bleeds were associated with an increased risk of 1-year mortality; however, non-access site thrombolysis in myocardial infarction bleeds were associated with a 4-fold increase in the risk of 1-year mortality, which was approximately twice as high as the risk associated with access (MULTISTRATEGY) were analyzed, only non-access site was associated with an increased risk of death or myocardial infarction 1 year after the PCI.
The current findings seem to differ, in part, with both of the above studies. In contrast to the study by Verheugt et al, 10 we found that the majority of bleeds (60%) were associated with the arterial access site. Although the exact reasons for the difference between the current study and that study cannot be known, the use of a more sensitive (able to capture more bleeding events) set of bleeding criteria in the current study could in part explain the difference. Of note, more than half of the access site bleeds in the current study were of BARC class 1, and a sizable proportion of them could have been undetected if less sensitive bleeding criteria were used. In contrast, only one fourth of non-access site bleeds were of BARC class 1. Differences between the MULTISTRATEGY substudy 11 and current study may be explained in part by the small number of patients/events in the MULTISTRATEGY study. Despite differences as to the frequency of bleeding site, the current study concurs with the study by Verheugt et al 10 on the association between bleeding and mortality. The use of the BARC hierarchical grading system in the current study enabled us to characterize patients more effectively into those with access and non-access site bleeding, and allowed us to explore the observed differences in association between bleeding site and mortality. First, hierarchical character of BARC definition allows us to better characterize bleeding events in terms of severity. Specifically, we found that 74.4% of non-access site bleeds but only 47.3% of access site bleeds were classified as severe (BARC class ≥2). Because there is a gradual increase in mortality with the increase in severity of bleeding as defined by BARC grading system, 16 this may explain the stronger association between non-access site bleeding and mortality. Second, patients with non-access site bleeding had a more adverse cardiovascular risk profile than patients with access site bleeding. Thus, occurrence of bleeding in these patients could either be a sign of poorer health or it may be more devastating in these patients because of their compromised health at the time of the bleed.
The impact of antithrombotic regimen on access versus non-access site bleeding is unclear. 10, 12 In a subgroup analysis of ACUITY trial, bivalirudin monotherapy reduced access and non-access site bleeding with femoral approach compared with heparin plus a glycoprotein IIb/IIIa, but not among patients undergoing a radial approach. 12 In the study by Verheugt et al 10 in which PCI was performed also mostly with the femoral approach, bivalirudin reduced access and all non-access site (bleeds not limited to the access site only) thrombolysis in myocardial infarction bleeds as compared with heparin plus a glycoprotein IIb/IIIa inhibitor. However, when analysis was focused strictly on non-access site bleeds, the difference in the frequency of bleeding between bivalirudin and heparin plus glycoprotein IIb/IIIa was not significant. 10 In the current study, periprocedural access and non-access site bleeding among patients receiving bivalirudin was significantly less frequent than among patients receiving heparin and abciximab. Compared with unfractionated heparin, bivalirudin therapy significantly reduced access site bleeding and its use was associated with a strong trend toward less non-access site bleeding as well. This finding may have implications. First, although bivalirudin use is an important component of bleeding avoidance strategies, 9 non-access site bleeding still remains a common complication associated with mortality even with the use of radial artery approach for vascular access. 14 Second, recent meta-analyses of randomized trials have reported a marked decrease of bleeding events but a neutral impact on mortality by bivalirudin compared with heparin monotherapy 26 or heparin plus glycoprotein IIb/IIIa inhibitors. 27 By reporting a significant reduction only in access site bleeding (a weaker correlate of mortality than non-access site bleeding), the current study may offer some explanation for the bleeding reduction-mortality relationship in patients treated with bivalirudin. However, this hypothesis needs corroboration by future studies.
There are some limitations to the present study. First, these data belong to patients in whom the vascular access was almost exclusively achieved by the femoral route and, as such, ought not be extrapolated to patients undergoing PCI by radial artery approach. Second, BARC bleeding criteria were applied retrospectively. However, the bleeding data were collected as part of each of the prospective studies pooled in this analysis. For every case with bleeding, source documentation-including patients' charts for those treated with coronary artery bypass surgery-was available and was reassessed. Detailed information on the occurrence of in-hospital bleeding including mild forms of it was recorded for all patients. However, because of the retrospective classification of the bleeding events according to the recent BARC criteria, we acknowledge the possibility of having missed some mild forms of bleeding belonging to BARC 1 class, particularly if they occurred after discharge to 30 days. Third, this pooled analysis did not include any patients with ST-segment-elevation myocardial infarction, a group shown to benefit from bleeding avoidance strategies. [28] [29] [30] However, this does not diminish the potential significance of these results to patients like those enrolled in these studies.
In conclusion, access and non-access site bleeding events occurring in the setting of PCI in patients with coronary artery disease are independently associated with an increased risk of 1-year mortality. Non-access site bleeding is a stronger correlate of mortality than access site bleeding. Only non-access site bleeding seems to offer prognostic information that is independent of and supplementary to that provided by cardiovascular risk factors and clinical characteristics.
